The HCPLive Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for C difficile, IBS and IBD, Crohn's disease, and more.
May 31st 2024
Using available literature, the review assesses our current understanding of AATD, emerging biomarkers, and the future of drug development.
Fidaxomicin, Oral Metronidazole Demonstrate Similar Clinical Efficacy Among Patients With C Diff
September 7th 2023Patients with CDI treated with oral metronidazole experienced significantly more first-line drug changes compared to those on fidaxomicin, although there were no significant differences observed in the global or clinical cure rate between the two treatments.
Vedolizumab Not Associated With Increased Risk of C Diff in Patients With IBD, Study Finds
September 6th 2023Vedolizumab, anti-TNF, and 5-ASA treatments were not linked to an increased risk of CDI, but investigators noted other baseline variables were significantly associated with CDI risk in patients with IBD.
Microbiota-Targeted Intervention Decreases IHTC in Patients With NAFLD
September 5th 2023The clinical trial compared outcomes in patients with NAFLD on a resistant starch diet to a control group over a 4-month period, with results suggesting microbiota dietary supplements may improve liver conditions.
HCV-Infected Liver Transplant Patients Benefit from DAA Use, Study Finds
September 2nd 2023Results from the retrospective cohort study indicated viral eradication with DAAs after liver transplantation improved liver function and patient survival after a long-term follow-up, even in cirrhotic patients.
Biden Administration, CMS Reveal First 10 Drugs Set for Price Negotiation
August 29th 2023On August 29, 2023, the Biden Administration debuted the list of the first 10 drugs identified for price negotiation under the Inflation Reduction Act. The list, which includes agents indicated for diabetes, heart failure, GI conditions, and arthritis, accounted for more than $50 billion in spending during the evaluation period.
AbbVie Submits Application to FDA for Risankizumab in Ulcerative Colitis
August 28th 2023AbbVie submitted regulatory applications to the FDA and EMA for rizankizumab 1200 mg intravenous induction dose and 180 mg and 360 mg subcutaneous maintenance dose following successful Phase 3 trials INSPIRE and COMMAND.
Age, Prior Vaccination Predict Future Vaccine Receipt in Patients with IBD
August 24th 2023When evaluating patient-education strategies among individuals with IBD, investigators found vaccine uptake was unaffected by educational videos and text-based interventions, identifying prior vaccine receipt as the strongest predictor of future vaccination.
No Difference in Pediatric Growth Rates with Infliximab Biosimilar vs Reference Agent
July 21st 2023A single-center retrospective study is offering clinicians insight into the effects of biosimilar infliximab use on weight, height, and BMI trajectories in pediatric patients with inflammatory bowel disease.